Plain-English translation of NCT07085559 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment called Meta10-BCMA CAR-T cells for patients with advanced blood cancers (multiple myeloma, plasma cell leukemia, or AL amyloidosis) that have stopped responding to other treatments. The medication is made by collecting your own immune cells, engineering them in the laboratory to better fight cancer, and then infusing them back into your body. Researchers want to learn whether this treatment is safe and whether it helps shrink or eliminate your cancer.
Many patients with advanced blood cancers run out of effective treatment options after trying multiple standard therapies. This new treatment is designed to work differently—by using your own immune system in a more powerful, engineered way—to help patients whose cancers are no longer responding to conventional medicines.
You likely qualify if…
You likely don't qualify if…
First, you will undergo a procedure to collect your immune cells from your blood (called leukapheresis). Then you'll receive chemotherapy to prepare your body for the new cells. After several days, the specially engineered immune cells will be infused back into you. You will need close follow-up care with blood tests and bone marrow exams before and after treatment to monitor how well the treatment works and check for any side effects. The study will track how your cancer responds and how the cells behave in your body over time.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Anhui Provincial Hospital
Collaborators
Leman Biotech Co., Ltd.
Enrollment target
~36 participants
Started
June 2025
Primary completion
June 2027
Age range
19 Years – 75 Years
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xingbing Wang, PhD
Anhui Provincial Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.